CNC

Business profile & competitive position

Centene Corp. operates in the Healthcare sector under the Medical - Healthcare Plans industry classification. The company is the largest Medicaid insurer, largest Marketplace insurer, and largest stand-alone Prescription Drug Plan provider in the United States, delivering managed care through Medicaid, Medicare Advantage, Prescription Drug Plans, Supplement products, and commercial Health Insurance Marketplace plans. Its model targets underserved populations through local brands backed by national infrastructure. For 2025, total revenues reached $194.8 billion, with 57% from Medicaid, 21% from Commercial, 19% from Medicare, and 3% from Other; operating cash flow was $5.1 billion. As of December 31, 2025, Centene served 27.6 million members, including 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. The margin profile, however, tempers the scale story. A -2.6% net margin and -24.0% ROE show that Centene's market leadership is not currently generating profitable returns. The structural scale remains a meaningful competitive fixture, but the negative figures signal that pricing, medical costs, or membership mix are pressuring the economics of that position right now.

Financial posture

Centene currently carries a $32.3 billion market capitalization and trades at a P/E of -6.3, a multiple that reflects reported losses rather than normalized earnings power. The net margin of -2.6% and ROE of -24.0% confirm a trailing loss-making posture, while a beta of 1.11 indicates the stock has moved slightly more than the broader market. The negative P/E is consistent with the margin data: aggregate revenue scale approaching $195 billion has not translated into bottom-line profitability in the most recent reporting period. For investors evaluating the name, the financial posture is one of a large, systemically important insurer with meaningful cash generation but with earnings metrics that need stabilization before the valuation can be read as a straightforward earnings multiple.

Strategic priorities & outlook

According to its most recent 10-K filing, Centene's operational focus is centered on three overlapping priorities: Medicare footprint refinement, Marketplace pricing correction, and policy advocacy. The company plans to continue refining its Medicare footprint so it overlaps more closely with Medicaid operations and to expand Dual-Eligible Special Needs Plan offerings as a long-term growth driver. Management is maintaining an enterprise-level focus on D-SNP products aligned with CMS requirements taking effect through 2030. On the Marketplace side, Centene is implementing 2026 corrective pricing actions in states covering 95% of Marketplace membership and expanding Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states. Separately, the company says it will advocate for policies and legislation aimed at preserving affordable Medicaid and Marketplace coverage as well as cost-effective PDP care. A final notable item from the filing is the December 2025 definitive agreement to divest the remaining Magellan Health businesses, signaling continued portfolio simplification.

Macro & geopolitical exposure

As a Medical - Healthcare Plans operator, Centene is exposed to the regulatory and fiscal mechanics of U.S. healthcare financing. The Medicaid line is directly tied to state budgets, federal matching formulas, and CMS rulemaking, meaning shifts in federal or state administration can alter reimbursement rates, eligibility rules, and expansion dynamics. The Medicare Advantage and PDP books are exposed to annual CMS rate announcements, star ratings, and Medicare Part D redesign policies. The Marketplace business depends on Affordable Care Act subsidies, exchange regulations, and the stability of the individual market. Broader macro factors also matter: medical-cost inflation, prescription-drug pricing policy, employment levels that drive Medicaid enrollment, and interest-rate movements affecting investment income on reserved capital. Unlike a global manufacturer, Centene has limited direct currency or commodity exposure, but its economics are tightly coupled to domestic health policy, federal spending negotiations, and judicial or administrative changes to healthcare law.

Recent developments

The most recent headline flow has centered on earnings guidance and valuation debate. On September 20, 2026, marketbeat.com reported that Centene reaffirmed its 2026 EPS outlook even as Medicaid membership decline deepens, framing the central tension for the stock: earnings targets holding while enrollment contracts. On September 18, 2026, zacks.com published two related pieces: one asking whether Centene stock is undervalued right now, and another including it among the best growth stocks to buy for that date. The same day, zacks.com also examined surging employer health costs and what that theme means for EHTH, CNC, and UNH. The cluster of coverage underscores investor interest in whether the insurer's scale and pricing actions can offset membership headwinds.

Earnings behavior & post-earnings drift

Centene has an unusually strong recent earnings record relative to the market's real expectation. Over the last eight reported quarters, the company beat in seven of them, for an 88% beat rate, and the average earnings surprise was 63.1%. The typical post-earnings price pattern has also leaned positive: the average 5-day move after earnings across those quarters was +2.83%, classified as an upward drift. The last four reports, listed from most recent to oldest, nevertheless show how choppy the immediate reaction can be. On July 28, 2026, Centene reported $2.51 EPS against an estimate of $1.09, a 130.3% surprise, yet the stock fell 3.27% the next day and gained only 0.25% over the following five days. On April 28, 2026, a $3.37 actual versus $2.23 estimate (51.1% surprise) produced an 8.9% next-day rally and a 6.88% five-day gain. The February 6, 2026 report, with actual EPS of -$1.19 versus estimate -$1.22007 (2.5% surprise), saw a -1.09% next-day drop but a 5.51% gain over the next week. And on October 29, 2025, actual EPS of $0.50 against estimate -$0.14475 (445.4% surprise) still led to a -6.21% next-day decline and -1.34% over five days. The pattern suggests beats are common, but the unofficial consensus often prices in even more. The next report is scheduled for October 27, 2026, before the open, with a consensus EPS estimate of $0.07.

For a deeper dive into how sell-side and quantitative models currently grade Centene's valuation, earnings trajectory, and risk factors, consult the full institutional verdict on the ticker page.